Clinical trials: Psoriatic-arthritis
Psoriatic Arthritis
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
This study will assess the efficacy and safety of secukinumab in patients with active psoriatic arthritis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
- Trial name
- FUTURE 1 (NCT01392326)
- Testing
- Secukinumab (75 mg), Secukinumab (150 mg)
- Where
- 110 sites in United States, Argentina and 17 more
- Volunteers
- 606 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis (PsO), Psoriasis Arthritis
Definition of Novel Optoacoustic Biomarkers of Psoriasis and Psoriatic Arthritis
This study investigates changes in the skin and joints of people with psoriasis (PsO) and psoriatic arthritis (PsA) using two non-invasive imaging methods called raster-scan optoacoustic mesoscopy (RSOM) and multispectral…
- Trial name
- MOJMI (NCT07885345)
- Testing
- Raster-Scan Optoacoustic Mesoscopy, Multispectral Optoacoustic Tomography, Skin Biopsy and Skin Sample Collection
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Psoriatic Arthritis
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis
Title Safety and Efficacy of Tofacitinib vs Methotrexate in the treatment of Psoriatic Arthritis- An Open Label Randomized single center study Psoriatic arthritis is defined as an inflammatory arthropathy associated with skin…
- Trial name
- PsOLSET-BD (NCT03736161)
- Testing
- Group A- Tofacitinib, Group B- Methotrexate
- Where
- Bangladesh
- Volunteers
- 61 people
- Sponsor
- Globe Pharmaceuticals Limited
Psoriatic Arthritis
Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis
MONITOR is a cohort study recruiting patients with a new diagnosis of psoriatic arthritis (PsA) which will establish outcomes using a pragmatic feasible 'treat to target' approach in a real-life clinic population.
- Trial name
- MONITOR (NCT03531073)
- Testing
- Methotrexate
- Where
- United Kingdom
- Volunteers
- 446 people
- Sponsor
- University of Oxford
Psoriatic Arthritis
PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis.
- Trial name
- PALACE2 (NCT01212757)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 98 sites in United States, Belgium and 14 more
- Volunteers
- 488 people
- Sponsor
- Amgen
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Enthesitis
Detection of Subclinical Enthesitis by Ultrasonography
Detection of subclinical enthesitis by ultrasonography
- Trial name
- NCT04209894
- Testing
- Ultrasound
- Where
- Turkey (Türkiye)
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
Arthritis, Psoriatic
Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis
The is a double-blind, placebo-controlled, randomized, and multicenter study consisting of a first treatment (FT) period followed by either an observation (OB) period and a re-treatment (RT) period or an open-label (OL) treatment…
- Trial name
- NCT00090129
- Testing
- Onercept
- Where
- 40 sites in United States, Canada
- Volunteers
- 854 people
- Sponsor
- EMD Serono
Rheumatoid Arthritis, Spondyloarthritis
Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
Background The risk for hospitalized infection (i.e. infection leading to hospitalization) in patients with inflammatory arthritis (rheumatoid arthritis (RA), psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA) treated…
- Conditions
- Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis
- Trial name
- NCT03496831
- Testing
- Biologic Agents
- Volunteers
- 7,500 people
- Sponsor
- Simon Krabbe
Psoriasis, Psoriatic Arthritis
Identification of New Prognostic Markers in Psoriatic Arthritis
Identification of possible markers associated with the onset and / or progression of psoriatic arthritis through comparison in patients with psoriasis alone (Ps) and patients with psoriasis with joint involvement (PsA), plasma…
- Trial name
- NCT03455166
- Testing
- Serum Markers
- Volunteers
- 100 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Rheumatic Diseases, Rheumatoid Arthritis (RA)
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
The CARe RAiSE project represents a pioneering translational initiative aimed at advancing precision medicine in the treatment of autoimmune rheumatic diseases.
- Conditions
- Rheumatic Diseases, Rheumatoid Arthritis (RA), Giant Cell Arteritis (GCA), Psoriatic Arthritis (PsA)
- Trial name
- CARe RAiSE (NCT07150000)
- Testing
- Ex Vivo Assay
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Bonn
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Characterize Demographics, Compliance, Tolerability and Safety in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Prescribed Adalimumab (Humira®) as Part of Routine Clinical Care
The primary objective of this post-marketing observational study was to obtain data on the characteristics (patient age/gender; disease type, severity and duration; disease specific treatment history; current concomitant…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- NCT01163916
- Where
- 43 sites in Russia
- Volunteers
- 252 people
- Sponsor
- Abbott
Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA)
Safety and Pharmacokinetics of LPX-TI641 in Rheumatoid Arthritis and Psoriatic Arthritis
The goal of this clinical trial is to study the drug LPX-TI641 in patients with rheumatoid arthritis and psoriatic arthritis. We will compare the safety and tolerability of LPX-TI641 to placebo that contains no drug.
- Trial name
- NCT06628206
- Testing
- LPX-TI641
- Where
- 6 sites in United States, Jordan
- Volunteers
- 48 people
- Sponsor
- LAPIX Therapeutics Inc.
Systemic Lupus Erythematosus, Sjogren's Syndrome
COVID-19 Vaccination in Rheumatic Disease Patients
The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.
- Conditions
- Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis
- Trial name
- NCT04839315
- Testing
- mRNA COVD19 vaccine
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Mayo Clinic
Psoriatic Arthritis
Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis
This is a Phase 2a study to investigate the efficacy, safety, tolerability, PK, and PD of ATI-450 versus placebo in patients with moderate to severe psoriatic arthritis.
- Trial name
- NCT05511519
- Testing
- ATI-450
- Where
- 22 sites in United States, Poland
- Volunteers
- 47 people
- Sponsor
- Aclaris Therapeutics, Inc.
Psoriatic Arthritis
FAPI-PET/CT in Psoriatic Arthritis
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation, such as IgG4-related disease.
- Trial name
- NCT05686876
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Psoriatic Arthritis
Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis
The current study will assess the real - life effectiveness of adalimumab in the management of articular and dermatological manifestations of moderate to severe Psoriatic Arthritis (PsA).
- Trial name
- Complete-PsA (NCT01559038)
- Where
- 41 sites in Canada
- Volunteers
- 483 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriatic Arthritis, Rheumatoid Arthritis
Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.
Different classes of biological targeted therapies (b-DMARDs) are available for psoriatic arthritis (PsA) and seronegative rheumatoid arthritis (RA) (TNF inhibitors, anti-IL23, anti-IL17).
- Trial name
- NCT05767814
- Testing
- Phenotyping of synovial immune and stromal cells
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 135 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Arthritis, Psoriatic, Arthritis, Rheumatoid
Effectiveness of Digital Rehabilitation (SIMPLI.REHAB) in Hand Arthritis
This study investigates the effectiveness of SIMPLI.REHAB, a digital tool employed as an interface for administering occupational rehabilitation programs to patients diagnosed with Rheumatoid and Psoriatic Arthritis.
- Conditions
- Arthritis, Psoriatic, Arthritis, Rheumatoid, Deformity, Hand, Limitation, Mobility
- Trial name
- NCT06077890
- Testing
- Digital Rehabilitation, Conventional Rehabilitation
- Where
- Portugal
- Volunteers
- 35 people
- Sponsor
- Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.